Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA

被引：0
|
作者：
Barnett, Reagan
Lanka, Sree M.
Clemens, Keelia M.
Kiedrowski, Lesli Ann
Babiker, Hani M.
Bryce, Alan Haruo
Meyer, Haley M.
Choi, Yujin
Garje, Rohan
Gao, Xin
Chang, Richard Y.
Jang, Albert
Gulhati, Pat
Bilen, Mehmet Asim
Barata, Pedro C.
机构：
[1] Guardant Hlth Inc, Redwood City, CA USA
[2] Tulane Univ, New Orleans, LA USA
[3] Mayo Clin Florida, Jacksonville, FL USA
[4] Mayo Clin, Phoenix, AZ USA
[5] Mayo Clin, Scottsdale, AZ USA
[6] Emory Univ, Atlanta, GA USA
[7] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[8] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[9] Harvard Med Sch, Boston, MA USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Tulane Univ, Sch Med, New Orleans, LA USA
[12] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2561
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).
    Florou, Vaia
    Floudas, Charalampos S.
    Maoz, Asaf
    Naqash, Abdul Rafeh
    Hildebrand, Gregory
    Sokol, Ethan
    Frampton, Garrett M.
    Puri, Sonam
    Swami, Umang
    Wilky, Breelyn A.
    Hosein, Peter Joel
    Trent, Jonathan C.
    Lopes, Gilberto
    Park, Wungki
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC).
    Ellis, Haley
    Klempner, Samuel J.
    Quintanilha, Julia C. F. C. F.
    Myer, Parvathi
    Lin, Douglas I.
    Panarelli, Nicole
    Fisher, Virginia
    Li, Gerald
    Huang, Richard S. P.
    Ross, Jeffrey S.
    Oxnard, Geoffrey R.
    Graf, Ryon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 46 - 46
  • [43] Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis (vol 9, e002553, 2021)
    Puzanov, I
    Subramanian, P.
    Yatsynovich, Y., V
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [44] Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes
    Xu, Jinxia
    Shao, Ruiyu
    Zhang, Xiaoru
    Yao, Deshun
    Han, Sugui
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2023, 47 (07)
  • [45] Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer
    Hill, Breana L.
    Graf, Ryon P.
    Shah, Kunal
    Danziger, Natalie
    Lin, Douglas, I
    Quintanilha, Julia
    Li, Gerald
    Haberberger, James
    Ross, Jeffrey S.
    Santin, Alessandro D.
    Slomovitz, Brian
    Elvin, Julia A.
    Ramez, Eskander
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (04) : 504 - 513
  • [46] High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).
    Florou, Vaia
    Park, Wungki
    Torres, Alfredo Enrique
    Algaze, Sandra
    Saravia, Diana
    Wilky, Breelyn A.
    Merchan, Jaime R.
    Hosein, Peter Joel
    Lockhart, Albert Craig
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] MR1 in combination with tumor mutational burden and PD-1/PD-L1 expression as a potentially novel clinical predictor for T cell exhaustion and immune checkpoint inhibitor response.
    Farha, Mark
    Jairath, Neil
    El Naqa, Issam
    Spratt, Daniel Eidelberg
    Lawrence, Theodore
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors
    Medioni, J.
    Brizard, M.
    Teixeira, L. O.
    Doucet, L.
    Ghrieb, Z.
    Angelergues, A.
    Oudard, S.
    Culine, S.
    Adotevi, O.
    Laheurte, C.
    Dragon-Durey, M-A.
    Laurent-Puig, P.
    Kiladjian, J-J.
    Doppler, V.
    Souttou, B.
    Wain-Hobson, S.
    Defrance, R.
    Huet, T.
    Langlade-Demoyen, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 136 - 136
  • [49] Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI)
    Xavier, Camila Braganca
    Guardia, Gabriela
    Lopes, Carlos Diego Holanda
    Awni, Beatriz Mendes
    Campos, Eduardo Felicio
    Alves, Joao Pedro
    Camargo, Anamaria Aranha
    Galante, Pedro Alexandre Favoretto
    Jardim, Denis L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
    Li, Yue
    Yang, Xinhua
    Zhu, Weijie
    Xu, Yuxia
    Ma, Jiangjun
    He, Caiyun
    Wang, Fang
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
12345